Extensive migration has led to the necessity of knowledge regarding the treatment of
migrants with different ethnical backgrounds. This is especially relevant for pharmacological …

The aim of personalized medicine is to detach from a “one-size fits all approach” and
improve patient health by individualization to achieve the best outcomes in disease …

Numerous studies in the field of psychopharmacological treatment have investigated the
possible contribution of genetic variability between individuals to differences in drug efficacy …

The empirical approach to drug choice and dosing in depression often results into
inadequate response and side effects. Pharmacogenetic (PGx) testing appears a promising …

Objective: To examine the effectiveness of genetic testing in a real-world setting and to
assess its impact on clinician treatment decisions. Method: This was a naturalistic …

Clinicians already face “personalized” medicine every day while experiencing the great
variation in toxicities and drug efficacy among individual patients. Pharmacogenetics studies …

Prader-Willi syndrome (PWS) is associated with co-morbid psychiatric symptoms (disruptive
behavior, anxiety, mood disorders, and psychosis) often requiring psychotropic medications …

Purpose: To investigate the predictive value of the risperidone and venlafaxine metabolic
ratios and CYP2D6 genotype. Methods: The determination of risperidone, 9 …

Early reports of clinical utility are published. The current evidence base for antidepressant
pharmacogenetics is, however, not yet empirically robust enough to inform routine …

Early discharge or reduced length of stay for inpatient psychiatric patients is related to
increased readmission rates and worse clinical outcomes including increased risk for …